Inclusion Criteria:

        Patient must be 45 years of age or less.

        Patient or the patient's legally authorized guardian must be fully informed about their
        illness and the investigational nature of the study protocol (including foreseeable risks
        and possible side effects), and must sign an informed consent in accordance with the
        institutional policies approved by the U.S. Department of Health and Human Services.

        Patients should have been off other investigational therapy for one month prior to entry in
        this study.

        Patient must have adequate organ function as below

        Adequate renal function defined as:

        Serum creatinine <2.0 x normal, or Creatinine clearance or radioisotope GFR > 40 ml/min/m2
        or >60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range

        Adequate liver function defined as:

        Total bilirubin <2.0 x normal; and SGOT (AST) or SGPT (ALT) <5.0 x normal

        Adequate cardiac function defined as:

        Shortening fraction of >27% by echocardiogram

        Hodgkin Lymphoma with either of the following:

        Primary induction failure (failure to achieve initial CR) and/or primary refractory
        disease.First relapse ; Early relapse (within 12 months off therapy) (excluding those who
        received no therapy or radiation therapy only for initial therapy); Late relapse (greater
        than 12 months off therapy). Only patients with recurrent Stage III or IV disease and/or
        those with B symptoms at relapse (all other late relapses are excluded); Second relapse;
        Third relapse.

        History of prior ablative auto HSCT or ineligible for an ablative auto HSCT or ≥25%
        residual disease after at least two reinduction chemotherapy cycles.

        EBV seropositive IgG HLA matched family or unrelated donor (MUD) HLA matched family donor
        (6/6 or 5/6) or matched unrelated adult donor (MUD) (7/8 or 8/8) All patients entered into
        the study ideally will have tumor tissue from the original diagnostic specimen and/or
        relapse reviewed centrally for confirmation of Hodgkin lymphoma. If no specimen is
        available, local pathology report documenting EBV positivity is acceptable. Appropriate
        immunophenotyping to confirm the diagnosis will be performed. In addition, in situ
        hybridization for EBV (LMP1, and/or EBER positivity) will be performed. All central
        morphologic analysis and immunohistochemical/insitu hybridization staining will be
        performed in the laboratory of Sherrie Perkins and Rodney Miles at the University of Utah.

        Exclusion Criteria:

        Patients with HD with 4th or greater CR, PR, and/or SD are ineligible. Patients with
        rapidly progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy
        are ineligible.

        EBV negative Hodgkin Lymphoma. Patients who don't have an eligible donor (outlined in 7.0)
        are ineligible. Women who are pregnant are ineligible. Negative pregnancy test in women of
        childbearing age is required.